Organigram Global (NASDAQ:OGI) versus Sharps Technology (NASDAQ:STSS) Head to Head Analysis

Organigram Global (NASDAQ:OGI) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Organigram Global and Sharps Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organigram Global	6.03%	-15.41%	-10.49%
Sharps Technology	N/A	-145.56%	-140.36%

Risk and Volatility

Organigram Global has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Insider & Institutional Ownership

34.6% of Organigram Global shares are held by institutional investors. Comparatively, 17.2% of Sharps Technology shares are held by institutional investors. 0.1% of Organigram Global shares are held by company insiders. Comparatively, 1.2% of Sharps Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Organigram Global and Sharps Technology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$185.07 million	1.08	-$17.70 million	$0.14	10.14
Sharps Technology	$204,120.00	348.54	-$282.50 million	($831.83)	0.00

Organigram Global has higher revenue and earnings than Sharps Technology. Sharps Technology is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Organigram Global and Sharps Technology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	1	0	2	0	2.33
Sharps Technology	1	0	0	0	1.00

Summary

Organigram Global beats Sharps Technology on 10 of the 13 factors compared between the two stocks.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.